[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586443":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":11,"id":62,"slug":11,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"The University of Texas Health Science Center, Houston","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SOLE","EXPERIMENTAL",null,[13],"Drug: SOLE",{"label":15,"type":16,"description":11,"interventionNames":17},"MOLE","ACTIVE_COMPARATOR",[18],"Drug: MOLE",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Participants will first receive LE at 1 g\u002Fkg\u002Fday, then will advance to 2 g\u002Fkg\u002Fday and lastly to 3 g\u002Fkg\u002Fday as tolerated to titrate based on triglyceride level \\\u003C250 mg\u002FdL, per clinical team",[9],{"type":21,"name":15,"description":22,"armGroupLabels":25,"otherNames":11},[15],[27],{"name":28,"affiliation":5,"role":29},"Lindsay Holzapfel, MD, MS","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Lindsay F Holzapfel, MD, MS","CONTACT","(713) 500-6422","Lindsay.N.Fleig@uth.tmc.edu",{"name":37,"role":33,"phone":38,"phoneExt":11,"email":39},"Emily Stephens","(713) 500-5734","Emily.K.Stephens@uth.tmc.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The University of Texas Health Science Center at Houston","RECRUITING","Houston","Texas","77030","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-95.36327,29.76328,{"lat":53,"lon":52},[56,58],{"name":28,"role":33,"phone":57,"phoneExt":11,"email":35},"713-500-6422",{"name":37,"role":33,"phone":38,"phoneExt":11,"email":39},{"type":29,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Lindsay Fleig Holzapfel, MD","Assistant Professor","100586443",false,"NCT06915441","Lipid Infusions to Optimize Nutrition Trial","Lipid Infusions to Optimize Nutrition (LION) and Minimize Bronchopulmonary Dysplasia and Neurodevelopmental Impairment in Extremely Preterm Infants: A Randomized Comparative Effectiveness Trial","LION","Inclusion Criteria:\n\n* inborn \\\u003C28 weeks gestational age (GA) or ≤1000g birth weight (BW)\n* survives until 12 hours after birth.\n\nExclusion Criteria:\n\n* Infants who are unable to be enrolled by 96 hours postnatal age\n* Major anomaly\n* Overt non-bacterial infection\n* Infants likely to expire soon defined as limiting or withdrawal of intensive care recommended or requested by the parents.","ALL","12 Hours","28 Weeks",{"count":73,"type":74},230,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","The purpose of this study is to identify survival free of bronchopulmonary dysplasia (BPD), fatty acid profiles, and early biochemical measures for oxidative stress comparing mixed oil lipid emulsion (MOLE) vs soybean oil-based lipid emulsion (SOLE) and to establish whether MOLE or SOLE is more effective in minimizing pulmonary outcomes, neonatal morbidities, long-term morbidity and mortality, and improving discharge growth and Bayley Scales of Infant Development Fourth Edition (BSID-IV) neurodevelopmental assessment at two years",[80,81],"Bronchopulmonary Dysplasia","Neurodevelopmental Impairment",[83,84],"soybean oil-based lipid emulsion (SOLE)","mixed oil lipid emulsion (MOLE)","2026-04-29",{"date":87,"type":88},"2026-05-05","ACTUAL",{"date":90,"type":74},"2026-05-01",{"date":92,"type":74},"2030-12-31",{"name":5,"class":6},1]